Oxysophocarpine induces anti-nociception and increases the expression of GABAAα1 receptors in mice

Molecular Medicine Reports

Volumn 7, Issue 6, 2013, Pages 1819-1825

  Xu, Tingting ^a   Li, Yuxiang ^b   Wang, Haiyan ^a   Xu, Yaqiong ^a   Ma, Lin ^a   Sun, Tao ^a   Ma, Hanxiang ^a   Yu, Jianqiang ^a  

^a NINGXIA MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

aminobutyric acid; aminobutyric acid type A; Analgesia; Oxysophocarpine

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1; ACETIC ACID; ALKALOID; ANALGESIC AGENT; FORMALDEHYDE; HOT WATER; OXYSOPHOCARPINE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BRAIN CORTEX; HIPPOCAMPUS; HOT PLATE TEST; IMMUNOHISTOCHEMISTRY; MOUSE; NOCICEPTION; NONHUMAN; PAIN; PROTEIN EXPRESSION;

ALKALOIDS; ANALGESICS; ANIMALS; CAMPANULACEAE; CENTRAL NERVOUS SYSTEM; MICE; MICE, INBRED ICR; NEURONS; PAIN MANAGEMENT; RECEPTORS, GABA-A; UP-REGULATION;

EID: 84877264520     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1414     Document Type: Article

References (42)

1. Millan MJ: Descending control of pain. Prog Neurobiol 66: 355-474, 2002.
2. Malcangio M and Bowery NG: GABA and its receptors in the spinal cord. Trends Pharmacol Sci 17: 457-462, 1996.
3. Zhang JT, Wang W and Duan ZH: Progress of research and application of matrine-type alkaloids. Prog Mod Biomed 7: 541-544, 2007 (In Chinese).
4. Rodrigues AL, da Silva GL, Mateussi AS, et al: Involvement of monoaminergic system in the antidepressant-like effect of the hydroalcoholic extract of Siphocampylus verticillatus. Life Sci 70: 1347-1358, 2002.
5. Trentin AP, Santos AR, Miguel OG, Pizzolatn MG, Yunes RA and Calixto JB: Mechanisms involved in the antinociceptive effect in mice of the hydroalcoholic extract of Siphocampylus verticillatus. J Pharm Pharmacol 49: 567-572, 1997.
6. Li ZHR: The pharmaceutical effect and clinical development of kushenin. West China J Pharm Sci 18: 435-437, 2003 (In Chinese).
7. Wang XH, Huang SK and Lin P: Pharmacokinetics and pharmacodynamics of sophocarpine and oxysophocarpine. J China Pharm Univ 23: 161-164, 1992 (In Chinese).
8. Yan L and Jiang YX: Studies of analgesia effect of oxysophoridien. Chin Tradit Herb Drugs 37: 1061-1062, 2006 (In Chinese).
9. Grant GJ, Vermenulen K, Zakowski MI, Stener M, Turndorf H and Langerman L: Prolonged analgesia and decreased toxicity with liposomal morphine in a mouse model. Anesth Analg 79: 706-709, 1994.
10. Goyal R and Anil K: Protective effect of alprazolam in acute immobilization stress-induced certain behavioral and biochemical alterations in mice. Pharmacol Rep 59: 284-290, 2007.
11. Eddy NB and Leimbach D: Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. J Pharmacol Exp Ther 107: 385-393, 1953.
12. Qian LW, Dai WH and Wang LL: Toxicity study on sophocarpine and oxysophocarpine in mice. Chin J Exp Tradit Med Formulae 18: 256-258, 2012 (In Chinese).
13. Dongmo AB, Nguelefack T and Lacaille-Dubois MA: Antinociceptive and anti-inflammatory activities of Acacia pennata wild (Mimosaceae). J Ethnopharmacol 98: 201-206, 2005.
14. Corrêa CR and Calixto JB: Evidence for participation of B1 and B2 kinin receptors in formalin-induced nociceptive response in the mouse. Br J Pharmacol 110: 193-198, 1993.
15. Vaz ZR, Filho VC, Yunes R and Calixto JB: Antinociceptive action of 2-(4-bromobenzoyl)-3-methyl-4,6-dimethoxy benzofuran, a novel xanthoxyline derivative on chemical and thermal models of nociception in mice. J Phamacol Exp Ther 278: 304-312, 1996.
16. Santos AR and Calixto JB: Further evidence for the involvement of tachykinin receptor subtypes in formalin and capsaicin models of pain in mice. Neuropeptides 31: 381-389, 1997.
17. Xu SY, Bian RL and Chen X (eds): Methods of pharmacological experiments. 3rd ed. The People's Medical Publishing House, Beijing, p702, 2002.
18. Le Bars D, Gozariu M and Cadden SW: Animal models of nociception. Pharmacol Rev 53: 597-652, 2001.
19. Thomsen M, Wörtwein G, Olesen MV, et al: Involvement of Y(5) receptors in neuropeptide Y agonist-induced analgesic-like effect in the rat hot plate test. Brain Res 1155: 49-55, 2002.
20. Tjølsen A, Berge OG, Hunskaar S, Rosland JH and Hole K: The formalin test: an evaluation of the method. Pain 51: 5-17, 1992.
21. Chau T: Pharmacological methods in the control of inflammation. In: Modern Methods in Pharmacology. Chang JY and Lewis AJ (eds). Alan R. Liss, New York, pp195-212, 1989.
22. Walwyn WM, Matsuka Y, Arai D, et al: HSV-1-mediated NGF delivery delays nociceptive deficits in a genetic model of diabetic neuropathy. Exp Neurol 198: 260-270, 2006.
23. Rujjanawate C, Kanjanapothi D and Panthony A: Pharmacological effect and toxicity of alkaloids from Gelsemium elegans Benth. J Ethnopharmacol 89: 91-95, 2003.
24. Hunskaar S and Hole K: The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain 30: 103-114, 1987.
25. Koster R, Anderson M and De Beer EJ: Acetic acid for analgesic screening. Fed Proc 18: 412-416, 1959.
26. Hendershot LC and Forsaith J: Antagonism of the frequency of phenylquinone-induced writhing in the mouse by weak analgesics and nonanalgesics. J Pharmacol Exp Ther 125: 237-240, 1959.
27. Collier HO, Dinneen LC, Johnson CA and Schneider C: The abdominal constriction response and its suppression by analgesic drugs in the mouse. Br J Pharmacol Chemother 32: 295-310, 1968.
28. Martire M, Castaldo P, D'Amico M, Preziosi P, Annuzito L and Taglialatela M: M channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals. J Neurosci 24: 592-597, 2004.
29. Lujan R: Subcellular regulation of metabotropic GABA receptors in the developing cerebellum. Cerebellum 6: 123-129, 2007.
30. Condés-Lara M, Rojas-Piloni G, Martínez-Lorenzana G, López-Hidalgo M and Rodríguez-Jiménez J: Hypothalamospinal oxytocinergic antinociception is mediated by GABAergic and opiate neurons that reduce A-delta and C fiber primary afferent excitation of spinal cord cells. Brain Res 1247: 38-49, 2009.
31. Barnard EA, Skolnick P, Olsen RW, et al: International Union of Pharmacology. XV. Subtypes of γ-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 50: 291-313, 1998.
32. Knabl J, Witschi R, Hösl K, et al: Reversal of pathological pain through specific spinal GABAA receptors subtypes. Nature 451: 330-334, 2008.
33. Whiting PJ, Bonnert TP, McKernan RM, et al: Molecular and functional diversity of the expanding GABAA receptor gene family. Ann N Y Acad Sci 868: 645-653, 1999.
34. Sieghart W: Structure, pharmacology, and function of GABAA receptor subtypes. Adv Pharmacol 54: 231-263, 2006.
35. Nutt D: GABAA receptors: subtypes, regional distribution, and function. J Clin Sleep Med 2: S7-S11, 2006.
36. Möhler H, Fritschy JM and Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther 300: 2-8, 2002.
37. Sieghart W and Sperk G: Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr Top Med Chem 2: 795-816, 2002.
38. Pirker S, Schwarzer C, Wieselthaler A, Sieghart W and Sperk G: GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience 101: 815-850, 2000.
39. Crestani F, Martin JR, Möhler H, Rudolph U: Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol 131: 1251-1254, 2000.
40. Melzack R and Wall PD: Pain mechanism: a new theory. Science 150: 971-979, 1965.
41. Wall PD: The substantia gelatinosa. A gate control mechanism set across sensory pathway. Trends Neurosci 3: 221-224, 1980.
42. Redecker C, Luhmann HJ, Hagemann G, Fritschy JM and Witte OW: Differential downregulation of GABAA receptor subunits in widespread brain regions in the freeze-lesion model of local cortical malformations. J Neurosci 20: 5045-5053, 2000.